For example, in pancreatic cancer and breast cancer models, combining Axl inhibition (e.g., bemcentinib) with radiation therapy or chemotherapy (such as paclitaxel or gemcitabine) reprograms tumor-associated macrophages (TAMs), increases antigen presentation, and improves CD8+ T cell infiltration, leading to more robust immune responses (125). The gene discussed is CD8A; the disease is neoplasm.